Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA9 | Q16790 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 1.00 |
| ▸ | CA4 | P22748 | 5/20 | 1.00 |
| ▸ | CA6 | P23280 | 5/20 | 1.00 |
| ▸ | CA5A | P35218 | 5/20 | 1.00 |
| ▸ | CA7 | P43166 | 5/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906360 | 1.00 | CA1 (1.00) | CA1CA2CA9CA12CA4 | |
| SCHEMBL435704 | 0.84 | CA1 (0.73) | CA1CA2CA9CA12CA4 | |
| SCHEMBL8496857 | 0.83 | CA1 (0.70) | CA1CA2CA9CA12CA4 | |
| SCHEMBL1186046 | 0.83 | CA2 (0.70) | CA1CA2CA9CA12CA4 | |
| SCHEMBL11323509 | 0.82 | CA2 (0.68) | CA1CA2CA9CA12CA4 | |
| SCHEMBL793608 | 0.82 | CA2 (0.69) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5737571 | 0.81 | CA1 (0.67) | CA1CA2CA9CA12CA4 | |
| SCHEMBL11323506 | 0.81 | CA2 (0.67) | CA1CA2CA9CA12CA4 | |
| SCHEMBL303829 | 0.81 | CA1 (0.68) | CA1CA2CA9CA12CA4 | |
| SCHEMBL5738131 | 0.81 | CA1 (0.68) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287040-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-29 | — | — | US | disclosed |
| EP-4355742-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-117813300-A | Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors | 缆图药品公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022266190-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9572792-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| CN-103153993-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (BS) | 2016-06-01 | — | — | CN | disclosed |
| EP-2594265-B1 | Ca ix-specific inhibitors | INST VIROLOGY (SK) | 2015-10-28 | — | — | EP | disclosed |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2015-09-24 | — | — | US | disclosed |
| US-6004948-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | NYCOMED AUSTRIA GMBH (AT) | 1999-12-21 | — | — | US | disclosed |
| EP-0848703-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | Nycomed Austria GmbH (AT) | 1998-06-24 | — | — | EP | disclosed |
| US-5606063-A | NMDA antagonists | MERRELL PHARMACEUTICALS INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1997003953-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | NYCOMED AUSTRIA GMBH (AT) | 1997-02-06 | — | — | WO | disclosed |
| EP-0573562-B1 | Dihydroquinoline NMDA antagonists | MERRELL PHARMA INC (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0573562-A1 | NMDA ANTAGONISTS. | MERRELL DOW PHARMA (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015565-A1 | NMDA ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-4180503-A | FOR DYEING POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | disclosed |
| US-4124581-A | FOR NATURAL AND SYNTHETIC FIBERS, COLORFAST | BAYER AKTIENGESELLSCHAFT (DE) | 1978-11-07 | — | — | US | disclosed |
| US-4060521-A | POLYAMIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287040-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | CDK2, CCNI, CDK20 | CA1 4212/4885CA2 3059/4885CA9 3304/4885 |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | CA1 4396/4885CA2 2566/4885CA9 4646/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | CA1 2506/4885CA2 849/4885CA9 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.